Literature DB >> 11187871

Immune tolerance induction and the treatment of hemophilia. Malmö protocol update.

E Berntorp1, J Astermark, E Carlborg.   

Abstract

The Malmö protocol for immune tolerance induction includes high doses of Factor VIII/IX, intravenous IgG and cyclophosphamide. If the inhibitor titer exceeds 10 Bethesda units at start, extracorporeal adsorption of IgG is performed using protein A. The protocol sometimes has to be repeated. A successful response may occur within a few weeks. In hemophilia A the success rate so far is 10/17 patients (15 high-responders, 2 low-responders) or 59%, whereas in hemophilia B 6/9 patients (8 high-responders, 1 low-responder), or 67%, have become tolerant. In one hemophilia B patient, a relapse occurred after 6 months. During a second treatment episode he developed an acute myocardial infarction, probably caused by replacement with prothrombin complex concentrate. We conclude that the Malmö protocol is efficient for induction of immune tolerance but the patients must be selected particularly with regard to inhibitor duration and time of last booster.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11187871

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  14 in total

1.  Hematopoietic stem cell transplantation improves the high incidence of neutralizing allo-antibodies observed in Hurler's syndrome after pharmacological enzyme replacement therapy.

Authors:  Muhammad Ameer Saif; Brian W Bigger; Karen E Brookes; Jean Mercer; Karen L Tylee; Heather J Church; Denise K Bonney; Simon Jones; J Ed Wraith; Robert F Wynn
Journal:  Haematologica       Date:  2012-02-27       Impact factor: 9.941

2.  Improved coagulation and haemostasis in haemophilia with inhibitors by combinations of superFactor Va and Factor VIIa.

Authors:  Vikas Bhat; Annette von Drygalski; Andrew J Gale; John H Griffin; Laurent O Mosnier
Journal:  Thromb Haemost       Date:  2015-10-15       Impact factor: 5.249

Review 3.  Immunomodulation for inhibitors in hemophilia A: the important role of Treg cells.

Authors:  Carol H Miao
Journal:  Expert Rev Hematol       Date:  2010-08       Impact factor: 2.929

Review 4.  Experience of Immune Tolerance Induction Therapy for Hemophilia A Patients with Inhibitors from a Single Center in India.

Authors:  Tulika Seth
Journal:  Indian J Hematol Blood Transfus       Date:  2019-11-04       Impact factor: 0.900

5.  Immunomodulation of transgene responses following naked DNA transfer of human factor VIII into hemophilia A mice.

Authors:  Carol H Miao; Peiqing Ye; Arthur R Thompson; David J Rawlings; Hans D Ochs
Journal:  Blood       Date:  2006-02-28       Impact factor: 22.113

Review 6.  FVIII inhibitors: pathogenesis and avoidance.

Authors:  Jan Astermark
Journal:  Blood       Date:  2015-02-23       Impact factor: 22.113

7.  Factor VIII inhibitors in hemophilia A: rationale and latest evidence.

Authors:  Char Witmer; Guy Young
Journal:  Ther Adv Hematol       Date:  2013-02

Review 8.  B-cell and T-cell epitopes in anti-factor VIII immune responses.

Authors:  Kathleen P Pratt; Arthur R Thompson
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

9.  Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment.

Authors:  Jinhai Wang; Jay Lozier; Gibbes Johnson; Susan Kirshner; Daniela Verthelyi; Anne Pariser; Elizabeth Shores; Amy Rosenberg
Journal:  Nat Biotechnol       Date:  2008-08       Impact factor: 54.908

Review 10.  Management of factor VIII inhibitors.

Authors:  Donna M Dimichele
Journal:  Int J Hematol       Date:  2006-02       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.